Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:HRMY NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$19.95+0.8%$20.89$19.00▼$26.58$2.44B0.851.32 million shs557,864 shsHRMYHarmony Biosciences$36.01-0.8%$35.39$26.47▼$41.61$2.07B0.84649,782 shs323,216 shsNVAXNovavax$7.85+0.7%$7.49$5.01▼$15.22$1.28B2.686.75 million shs3.26 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.05%-2.85%-10.89%-23.46%-0.55%HRMYHarmony Biosciences-3.28%-4.40%+3.89%+1.97%+0.72%NVAXNovavax+5.27%+2.77%+15.75%+4.56%-34.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$19.95+0.8%$20.89$19.00▼$26.58$2.44B0.851.32 million shs557,864 shsHRMYHarmony Biosciences$36.01-0.8%$35.39$26.47▼$41.61$2.07B0.84649,782 shs323,216 shsNVAXNovavax$7.85+0.7%$7.49$5.01▼$15.22$1.28B2.686.75 million shs3.26 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.05%-2.85%-10.89%-23.46%-0.55%HRMYHarmony Biosciences-3.28%-4.40%+3.89%+1.97%+0.72%NVAXNovavax+5.27%+2.77%+15.75%+4.56%-34.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$33.2066.38% UpsideHRMYHarmony Biosciences 3.00Buy$51.0041.62% UpsideNVAXNovavax 2.13Hold$14.2982.10% UpsideCurrent Analyst Ratings BreakdownLatest CPRX, HRMY, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.008/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.008/19/2025CPRXCatalyst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$10.00 ➝ $9.007/21/2025HRMYHarmony BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.007/10/2025HRMYHarmony BiosciencesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$54.00 ➝ $55.007/10/2025HRMYHarmony BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$33.006/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$6.006/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M4.97$2.47 per share8.09$6.10 per share3.27HRMYHarmony Biosciences$714.73M2.90$2.83 per share12.74$11.56 per share3.12NVAXNovavax$682.16M1.87N/AN/A($3.89) per share-2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.6512.109.370.8037.36%40.78%35.36%11/5/2025 (Estimated)HRMYHarmony Biosciences$145.49M$3.1011.6311.580.4423.44%26.34%17.71%11/4/2025 (Estimated)NVAXNovavax-$187.50M$2.283.4598.060.1039.20%-142.33%28.65%11/11/2025 (Estimated)Latest CPRX, HRMY, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million8/5/2025Q2 2025HRMYHarmony Biosciences$0.78$0.68-$0.10$0.68$204.37 million$200.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.716.55HRMYHarmony Biosciences0.203.843.80NVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%HRMYHarmony Biosciences86.23%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%HRMYHarmony Biosciences23.60%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.39 million109.66 millionOptionableHRMYHarmony Biosciences20057.53 million43.96 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableCPRX, HRMY, and NVAX HeadlinesRecent News About These CompaniesNovavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 4 at 3:04 PM | seekingalpha.comNuvaxovid® Now Approved in Japan Triggering Takeda Milestone PaymentSeptember 4 at 8:00 AM | prnewswire.comNovavax ‘applauds’ President Trump’s call for available COVID-19 vaccine dataSeptember 4 at 2:44 AM | msn.comNovavax to Participate in the Cantor Global Healthcare ConferenceSeptember 3 at 10:54 AM | finance.yahoo.comOMERS ADMINISTRATION Corp Takes $1.28 Million Position in Novavax, Inc. $NVAXSeptember 3 at 4:59 AM | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Receives $14.29 Consensus PT from AnalystsSeptember 3 at 2:25 AM | americanbankingnews.comOptimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy RatingSeptember 2 at 8:11 AM | tipranks.comRafferty Asset Management LLC Sells 80,502 Shares of Novavax, Inc. $NVAXSeptember 2 at 5:05 AM | marketbeat.comInvesco Ltd. Boosts Stake in Novavax, Inc. $NVAXSeptember 2 at 3:30 AM | marketbeat.comFY2025 Earnings Forecast for Novavax Issued By HC WainwrightSeptember 2 at 2:28 AM | marketbeat.comHC Wainwright Comments on Novavax FY2025 EarningsSeptember 2 at 2:27 AM | americanbankingnews.comNuveen LLC Purchases New Position in Novavax, Inc. $NVAXSeptember 1, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 1, 2025 | marketbeat.comQ3 Earnings Forecast for Novavax Issued By HC WainwrightAugust 31, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Novavax (NASDAQ:NVAX)August 30, 2025 | marketbeat.comKohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by AnalystsAugust 30, 2025 | tipranks.comHC Wainwright Initiates Coverage on Novavax (NASDAQ:NVAX)August 30, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for Novavax Q3 Earnings?August 30, 2025 | americanbankingnews.comNovavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLAAugust 29, 2025 | finance.yahoo.comRobert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk GroupsAugust 28, 2025 | msn.comNovavax (NVAX) Is Up After FDA Approves Updated Nuvaxovid for Key High-Risk Groups—What's ChangedAugust 28, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPRX, HRMY, and NVAX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$19.95 +0.15 (+0.78%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Harmony Biosciences NASDAQ:HRMY$36.01 -0.29 (-0.80%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Novavax NASDAQ:NVAX$7.84 +0.06 (+0.71%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
